THE MEDICINES PATENT POOL AND GILEAD SCIENCES SIGN LICENCE FOR BICTEGRAVIR
The MPP announced on 4 October 2017 a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen.
The Medicines Patent Pool Welcomes Extension of MPP-Gilead HIV Licences to Include Belarus, Malaysia and Ukraine
The MPP welcomes biopharmaceutical company Gilead Sciences' announcement that it will extend its HIV licences signed with the MPP to include three additional countries, namely Belarus, Malaysia and Ukraine.
BRISTOL-MYERS SQUIBB, MEDICINES PATENT POOL EXTEND LICENCE FOR ATAZANAVIR TO 122 DEVELOPING COUNTRIES
The MPP has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb (BMS) to further increase access to atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children.
Geneva, 11 October 2017 — The Medicines Patent Pool (MPP) announced that it has signed a Memorandum of Understanding (MoU) with Otsuka to accelerate the development and manufacturing of, and access to, paediatric formulations containing delamanid for multidrug-resistant tuberculosis (MDR-TB).
Delamanid 50mg tablet was recently added to the World Health Organization’s Essential Medicines List for Children signalling its priority for health programmes globally. Otsuka is currently developing a suitable paediatric formulation of the treatment for younger children.
The MoU outlines broad areas of collaboration between the parties, including seeking funding to have a third-party manufacturer develop appropriate paediatric formulations, and engaging in necessary licensing activities to move this forward. Importantly, it also envisions the parties seeking out future areas of cooperation in the field of MDR-TB treatment to address broader unmet patient needs.
The MPP, originally focused on HIV treatment acce...
As part of a novel, once-daily, single-tablet HIV treatment, bictegravir could offer new option for people living with HIV in low- and middle-income countries
Geneva, 4 October 2017 — The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen. The licence allows manufacturers to develop and sell generic medicines containing BIC, if approved in the United States, in 116 low- and middle-income countries where more than 30 million people live with HIV.
“Bictegravir-containing combinations could offer improved, simplified treatment options, crucial for people living in resource-limited settings,” said Greg Perry, Executive Director of the Medicines Patent Pool. “With this new licence, we look forward to our long-running collaboration with Gilead Sciences continuing to deliver significant results.”
Bictegravir is an integrase inhibitor in the same class...
Extension of 2013 agreement allows an additional 1.4 million people living with HIV to benefit from sublicensed generics of World Health Organization-recommended antiretroviral
Paris, 25 July 2017 — The Medicines Patent Pool (MPP) has signed an extension of its licensing agreement with biopharmaceutical company Bristol-Myers Squibb (BMS) to further increase access to atazanavir (ATV), part of the World Health Organization-preferred second-line treatment for adults and children.
Announced during an MPP-jointly hosted satellite at the 9th International AIDS Society Conference on HIV Science in Paris this evening, the amendment adds 12 countries to the 110 included in the original 2013 agreement. Home to 1.4 million people living with HIV (PLHIV), the additional countries are: Algeria, Cook Islands, Egypt, Equatorial Guinea, Indonesia, Malaysia, Morocco, Niue, the Philippines, Tunisia, Ukraine and Vietnam. The agreement now covers 89% of PLHIV in low- and middle-income countries.
“Our ATV licence has al...
“Successful cooperation of the Ministry of Health of Belarus with the Medicines Patent Pool is crucial in light of our current work to achieve the “90-90-90” goals and put an end to the epidemic in the country which is only possible when access to affordabl...”